{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:00:40Z","timestamp":1790373640950,"version":"4.1.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"DOI":"10.1093\/oncolo\/oyag238","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:57:46Z","timestamp":1783511866000},"source":"Crossref","is-referenced-by-count":0,"title":["Redefining the mCRPC frontline: lessons from PEACE-3 and BRCAaway in the post-ARPI era"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-3650","authenticated-orcid":false,"given":"Giuseppe Luigi","family":"Banna","sequence":"first","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth, PO6 3LY,","place":["United Kingdom"]},{"name":"Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth , Portsmouth, PO1 2EF,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2412-1310","authenticated-orcid":false,"given":"Giuseppe","family":"Neola","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth, PO6 3LY,","place":["United Kingdom"]},{"name":"Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth , Portsmouth, PO1 2EF,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2173-8245","authenticated-orcid":false,"given":"Fabrizio","family":"Di Costanzo","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University Centre for Cancer , Newcastle Upon Tyne, NE2 4AD,","place":["United Kingdom"]},{"name":"Northern Centre for Cancer Care, Newcastle Hospitals NHS Foundation Trust , Newcastle Upon Tyne, NE7 7DN,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4668-4765","authenticated-orcid":false,"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University Centre for Cancer , Newcastle Upon Tyne, NE2 4AD,","place":["United Kingdom"]},{"name":"Northern Centre for Cancer Care, Newcastle Hospitals NHS Foundation Trust , Newcastle Upon Tyne, NE7 7DN,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2026092517311892500_oyag238-B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.2026.44.7_suppl.15","article-title":"Final overall survival results from the EORTC 1333\/PEACE-3 trial: enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer","volume":"44","author":"Gallardo","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026092517311892500_oyag238-B2","article-title":"Overall survival from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway)","author":"Hussein","year":"2026","journal-title":"ASCO GU"},{"key":"2026092517311892500_oyag238-B3","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1158\/1535-7163.MCT-23-0724","article-title":"Exploring DNA damage repair therapeutics in prostate cancer beyond BRCAness","volume":"25","author":"Di Costanzo","year":"2026","journal-title":"Mol Cancer Ther"},{"key":"2026092517311892500_oyag238-B4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer (PROpel): a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026092517311892500_oyag238-B5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, double-blind, phase 3 trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"key":"2026092517311892500_oyag238-B6","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer (MAGNITUDE): final overall survival analysis","volume":"8","author":"Chi","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"2026092517311892500_oyag238-B7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41391-020-0222-6","article-title":"Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"23","author":"Mori","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026092517311892500_oyag238-B8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2967\/jnumed.122.264456","article-title":"Safety and survival outcomes of 177Lu-prostate-specific membrane antigen therapy in patients with metastatic Castration-Resistant prostate cancer with prior 223Ra treatment: the RALU Study","volume":"64","author":"Rahbar","year":"2023","journal-title":"J Nucl Med"},{"key":"2026092517311892500_oyag238-B9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"177LuLu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (Enza-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026092517311892500_oyag238-B10","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag238\/68741442\/oyag238.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag238\/68741442\/oyag238.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag238\/68741442\/oyag238.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:31:23Z","timestamp":1790371883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag238\/8729397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag238","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,7,9]]},"article-number":"oyag238"}}